REGENERATIVE THERAPIES MARKET ANALYSIS

Market Challenges And Opportunities

Global Regenerative Therapies Market- Restraints

Challenges in Market Growth: High Treatment Costs and Limited Reimbursement Policies The regenerative therapy market faces hurdles in its growth trajectory due to the high costs associated with treatment and inadequate reimbursement policies. This creates barriers for patients seeking these therapies. For example, many stem cell treatments are categorized as experimental, resulting in limited insurance coverage and significant out-of-pocket expenses for patients. Medicare, for instance, only covers U.S FDA-approved treatments such as allogeneic transplantation.

As per an article published by DVC Stem in July 2022, Stem cell therapy costs range from US$ 5,000 to US$ 50,000, depending on factors such as the type, number, and quality of cells used, as well as their source.

December 2021, Novartis's gene therapy product, Zolgensma, is a one-time treatment for spinal muscular atrophy with a price of US$ 2.12 million per infusion.

Restraints & Challenges:

• Challenges in Market Growth

Global Regenerative Therapies Market – Driver

 Growing Investments Drive Research and Collaboration in the Regenerative Medicine Market

Heightened investments in the regenerative medicine market have sparked extensive research and development initiatives, as numerous investors pour funds into start-up firms dedicated to advancing innovative therapies and products within the industry. Consequently, this has opened avenues for notable mergers, research collaborations, and partnerships, enabling the sharing of benefits derived from R&D endeavors.

Availability of Funding and Rising Investments Drive Regenerative Medicine Research

Increased funding and investments in the regenerative medicine field have spurred extensive research and development activities. The demand for improved therapies for various medical conditions has led to a surge in funding availability. Investments in the sector have reached significant levels, with key investors such as Amgen, Sanofi, and Gilead Sciences playing a prominent role. This financial support has facilitated the exploration of innovative solutions, including new cell therapies, gene therapies, and tissue-engineered products, driving advancements in regenerative medicine research.

For instance , The Alliance for Regenerative Medicine (ARM) reported that investments in the regenerative medicine sector reached USD 22,700 million in 2021. Key investors such as Amgen, Sanofi, and Gilead Sciences exceeded the previous year’s total by surpassing USD 19,900 million in 2020.